Summit Therapeutics SMMT Invested capital
Discontinued — last reported Q1 '26
Invested capital at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's invested capital?
- Summit Therapeutics (SMMT) reported invested capital of $557.73M in Q1 2026.
- How has Summit Therapeutics's invested capital changed year-over-year?
- Summit Therapeutics's invested capital increased by 62.6% year-over-year, from $343.1M to $557.73M.
- What is the long-term trend for Summit Therapeutics's invested capital?
- Over 5 years (2020 to 2025), Summit Therapeutics's invested capital has grown at a 117.9% compound annual growth rate (CAGR), from $13.5M to $663.38M.
- What does invested capital mean?
- The capital — debt plus equity, net of idle cash — that funds the operating business.
- How do you interpret invested capital?
- A level, read mainly through ROIC (NOPAT ÷ invested capital). Growing invested capital is only good if returns on it stay above the cost of capital.
- How does invested capital compare across companies?
- Used as the base for ROIC; the definition is sector-sensitive, so banks and insurers are best excluded.